logo

Atopic dermatitis (AD), the most common form of eczema, is a chronic inflammatory skin disorder that affects individuals of all ages, races, and geographic regions worldwide.

We are currently recruiting participants 18 years and older with moderate-to-severe eczema, also known as atopic dermatitis, to participate in a clinical study. This study is being done to evaluate the safety and efficacy (how well the drug works) of an injectable (like a shot) drug known as APG777.

Study participation will last approximately 2 years and comprises of 22 study visits. The study will include of 52 weeks of treatment followed by approximately 48-52 weeks of follow-up period. For the first 16 weeks of treatment, participants will have a 2 in 3 (66.6%) chance to receive APG777 and 1 in 3 (33.3%) chance to receive the placebo (shots with no study drug). After 16 weeks of treatment, all participants will receive APG777.   

Visits take approximately 2 to 4 hours depending on which tests need to be completed during the visit. 

Blood samples will be collected from all participants at the first visit and throughout the study.

An electrocardiogram to check heart health will be taken at visit 1 and medical photography will be used to evaluate your eczema over time. An eye exam will also be performed at visit 1 and at the end of the study as part of a comprehensive safety evaluation during this study.

Compensation for time and travel may be available. There will be no cost to you for taking part in this study and you will be provided with all study medication, examinations and medical care related to the study.

 See if you are eligible for the study!


Visits
Total
Length
Procedures
Study Length
Total
22 visits over approximately 2 years
Length
2 to 4 hours
Procedures
Blood samples, electrocardiogram, medical photography, comprehensive eye exam
Study Length
52 weeks of treatment and approximately 48-52 weeks of follow up period
Summary
A Two-Part, Multicenter, Randomized, Double-Blind, Placebo-controlled study to evaluate the safety and efficacy of APG 777 in Patients with Moderate-to-Severe Atopic Dermatitis
Condition
Atopic Dermatitis (Eczema)
Treatment
APG777

There are 18 locations for this study

Frontier Dermatology

Frontier Dermatology

Mill Creek, Washington, 98012, United States
Wilmington Dermatology Center

Wilmington Dermatology Center

Wilmington, North Carolina, 28405, United States
Lawrence J. Green, MD LLC

Lawrence J. Green, MD LLC

Rockville, Maryland, 20850, United States
ALLCUTIS Research, LLC

ALLCUTIS Research, LLC

Portsmouth, New Hampshire, 03810, United States
Tennesse Clinical Research Center

Tennesse Clinical Research Center

Nashville, Tennessee, 37215, United States
Virginia Clinical Research, Inc.

Virginia Clinical Research, Inc.

Norfolk, Virginia, 23502, United States
Lynderm Research

Lynderm Research

Markham, Ontario, L3P1X3, Canada
First OC Dermatology Research Inc.

First OC Dermatology Research Inc.

Fountain Valley, California, 92708, United States
Dermatologists of Southwest Ohio

Dermatologists of Southwest Ohio

Mason, Ohio, 45040, United States
Research Toronto

Research Toronto

Toronto, Ontario, M4W 2N4, Canada
Brunswick Dermatology Center

Brunswick Dermatology Center

Fredericton, New Brunswick, E3B1G9, Canada
Therapeutics Clinical Research Medical

Therapeutics Clinical Research Medical

San Diego, California, 92123, United States
Driven Research, LLC

Driven Research, LLC

Coral Gables, Florida, 33134, United States
Innovaderm Research Inc.

Innovaderm Research Inc.

Montréal, Quebec, H2X 2V1, Canada
Revival Research Institute

Revival Research Institute

Troy, Michigan, 48084, United States
Skin Centre for Dermatology

Skin Centre for Dermatology

Peterborough, Ontario, K9J5K2, Canada
Centre de Recherche Dermatologique du Quebec

Centre de Recherche Dermatologique du Quebec

Québec, Quebec, G1V 4X7, Canada
Progressive Clinical Research

Progressive Clinical Research

San Antonio, Texas, 78213, United States
Rectangle 191

Are you a researcher or representative of a clinical site?

Join our network of clinical sites and be at the forefront of innovation in clinical research.